Stem Cell Transplantation in Treatment of NonHodgkins Lymphoma

Stem Cell Transplantation in Treatment of NonHodgkins Lymphoma: "Stem Cell Transplantation in Treatment of NonHodgkins Lymphoma, SPPI Stem Cell Stock"

Prior to stem cell transplantation to a patient, the existing disease must be eradicated. Therefore, patients undergo conditioning regimens to eliminate, in the case of blood cancers, all or most of the tumor cells. This also destroys the patient’s blood generating (hematopoietic) system. Following conditioning, stem cells either derived from the patient’s own system (autologous) or from a matched donor (allogeneic) are introduced to the patient to renew the hematopoietic system. 

“These data solidify the role of ZEVALIN in treatment regimens for lymphoma patients,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc. “These presentations confirm our belief that ZEVALIN will continue to show strong data in a range of protocols to prepare lymphoma patients for these life-saving procedures.” 

Ajay K. Gopal, MD, Assistant Professor of Medical Oncology at the University of Washington School of Medicine and an Assistant Member of the Clinical Research Division of the Fred Hutchinson Cancer Research Center, presented data on the use of ZEVALIN, Fludarabine, and TBI based Non-Myeloablative Allogenic Transplant Conditioning for High-Risk B-Cell lymphomas (n=40). Non-myeloablative allogeneic transplantation (NMAT) can provide prolonged remissions in patients with advanced B-cell lymphoma via the graft versus lymphoma effect, though patients and donors need to be carefully selected. Dr. Gopal’s data indicated that use of ZEVALIN in NMAT is safe and feasible, and can lead to early objective responses and prolonged disease control in a subset of patients. 

Dr. Gopal’s ASH presentation is entitled Y-90 Ibritumomab Tiuxetan, Fludarabine, and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for High-Risk B-Cell Lymphoma. ASH Abstract #33.